TORCETRAPIB

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
UNII 4N4457MV2U
EPA CompTox DTXSID20180873

Structure

InChI Key CMSGWTNRGKRWGS-NQIIRXRSSA-N
Smiles CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C(=O)OC)C[C@H]1CC
InChI
InChI=1S/C26H25F9N2O4/c1-4-18-12-21(19-11-15(24(27,28)29)6-7-20(19)37(18)23(39)41-5-2)36(22(38)40-3)13-14-8-16(25(30,31)32)10-17(9-14)26(33,34)35/h6-11,18,21H,4-5,12-13H2,1-3H3/t18-,21+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C26H25F9N2O4
Molecular Weight 600.48
AlogP 8.2
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 0.0
Number of Rotational Bond 5.0
Polar Surface Area 59.08
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 41.0

Bioactivity

Mechanism of Action Action Reference
Cholesteryl ester transfer protein inhibitor INHIBITOR PubMed
Protein: Cholesteryl ester transfer protein
Description: Cholesteryl ester transfer protein
Organism : Homo sapiens
P11597 ENSG00000087237
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Ion channel Other ion channel Pore-forming toxins (proteins and peptides)
- 3-110 - - -
Assay Description Organism Bioactivity Reference
Ex vivo inhibition of CETP in normal chow diet-fed cynomolgus monkey at 3 mg/kg, po for 5 days by Roar assay Macaca fascicularis 35.0 %
Ex vivo inhibition of CETP in normal chow diet-fed cynomolgus monkey at 10 mg/kg, po for 5 days by Roar assay Macaca fascicularis 66.0 %
Ex vivo inhibition of CETP in normal chow diet-fed cynomolgus monkey at 30 mg/kg, po for 5 days by Roar assay Macaca fascicularis 85.0 %
Inhibition of human plasma CETP assessed as [3H]cholesterol ester transfer after 18 hrs by scintillation proximity assay Homo sapiens 3.0 nM
Inhibition of CETP assessed as cholesterol ester transfer after 4 hrs by microemulsion based fluorescence assay None 18.0 nM
Inhibition of human plasma CETP assessed as cholesterol ester transfer after 24 hrs by fluorescence assay Homo sapiens 20.0 nM
Inhibition of CETP-mediated BODIPY-labeled cholesteryl ester transfer after 45 mins by FRET analysis None 13.0 nM
Inhibition of CETP in human plasma assessed as reduction in fluorescent intensity by fluorescence analysis Homo sapiens 39.0 nM
Inhibition of CETP in human plasma assessed as transfer of fluorescently labelled cholesteryl ester to VLDL by fluorimetry Homo sapiens 39.0 nM
Inhibition of [3H]cholesteryl ester transfer from HDL to LDL in human CETP expressed transgenic mouse coexpressing apoB-100 at 30 mg/kg, po measured at 8 hrs relative to predose condition Mus musculus 25.0 %
Inhibition of [3H]cholesteryl ester transfer from HDL to LDL in human CETP expressed transgenic mouse coexpressing apoB-100 at 30 mg/kg, po measured at 4 hrs relative to predose condition Mus musculus 31.0 %
Inhibition of [3H]cholesteryl ester transfer from HDL to LDL in human CETP expressed transgenic mouse plasma coexpressing apoB-100 at 30 mg/kg, po measured at 2 hrs relative to predose condition Mus musculus 31.0 %
Inhibition of [3H]cholesteryl ester transfer from HDL to LDL in human CETP expressed transgenic mouse coexpressing apoB-100 at 30 mg/kg, po Mus musculus 160.0 nM
Inhibition of CETP-mediated [3H]cholesteryl ester transfer activity in human plasma after 2.5 hrs by scintillation counter Homo sapiens 110.0 nM
In vivo inhibition of CETP in human whole plasma at 120 mg for 14 days Homo sapiens 50.0 nM
Inhibition of CETP in human plasma measured every 30 mins for 120 mins by fluorescence method Homo sapiens 18.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 1.03 %
Inhibition of human recombinant CETP assessed as reduction in [3H]CE/HDL transfer incubated for 4 hrs by scintillation proximity assay Homo sapiens 12.0 nM
Inhibition of CETP in human whole plasma assessed as reduction in [3H]-CE/HDL transfer incubated for 2.5 hrs by topcount scintillation counting assay Homo sapiens 100.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 14.23 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 6.599 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.13 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.13 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.13 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.13 %

Cross References

Resources Reference
ChEBI 49203
ChEMBL CHEMBL479527
DrugBank DB06281
FDA SRS 4N4457MV2U
PDB 0RP
PubChem 159325
SureChEMBL SCHEMBL49081
ZINC ZINC000008214714
CONTENTS